These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society. Toyoda K; Koga M; Iguchi Y; Itabashi R; Inoue M; Okada Y; Ogasawara K; Tsujino A; Hasegawa Y; Hatano T; Yamagami H; Iwama T; Shiokawa Y; Terayama Y; Minematsu K Neurol Med Chir (Tokyo); 2019 Dec; 59(12):449-491. PubMed ID: 31801934 [No Abstract] [Full Text] [Related]
5. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT). Mori E; Minematsu K; Nakagawara J; Yamaguchi T; J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535 [TBL] [Abstract][Full Text] [Related]
6. [Guidelines for intravenous thrombolytic therapy in acute ischemic stroke with special reference to those by the Ad Hoc Committee of the Japan Stroke Society]. Minematsu K No To Shinkei; 2006 Nov; 58(11):915-21. PubMed ID: 17133996 [No Abstract] [Full Text] [Related]
7. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia. Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225 [TBL] [Abstract][Full Text] [Related]
8. Role of tissue plasminogen activator in acute ischemic stroke. Hatcher MA; Starr JA Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027 [TBL] [Abstract][Full Text] [Related]
10. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan. Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704 [TBL] [Abstract][Full Text] [Related]
11. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience. Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460 [TBL] [Abstract][Full Text] [Related]
12. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset. Lorenzano S; Toni D; Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526 [TBL] [Abstract][Full Text] [Related]
14. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Demaerschalk BM; Kleindorfer DO; Adeoye OM; Demchuk AM; Fugate JE; Grotta JC; Khalessi AA; Levy EI; Palesch YY; Prabhakaran S; Saposnik G; Saver JL; Smith EE; Stroke; 2016 Feb; 47(2):581-641. PubMed ID: 26696642 [TBL] [Abstract][Full Text] [Related]
15. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Yoneda Y; Yamamoto S; Hara Y; Ohta K; Matsushita M; Yamamoto D; Yamashita H; Hosoda K Clin Neurol Neurosurg; 2007 Sep; 109(7):567-70. PubMed ID: 17573188 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. O'Brien EC; Rose KM; Patel MD; Murphy CV; Rosamond WD J Stroke Cerebrovasc Dis; 2012 Oct; 21(7):541-6. PubMed ID: 21236701 [TBL] [Abstract][Full Text] [Related]
17. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital]. Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212 [TBL] [Abstract][Full Text] [Related]
18. Intravenous Alteplase for Acute Ischemic Stroke in Taiwan: Can We Expand the National Health Insurance's Reimbursement Criteria? Hsieh CY Acta Neurol Taiwan; 2017 Mar; 26(1):1-2. PubMed ID: 28752507 [TBL] [Abstract][Full Text] [Related]
19. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Shobha N; Buchan AM; Hill MD; Cerebrovasc Dis; 2011; 31(3):223-8. PubMed ID: 21178345 [TBL] [Abstract][Full Text] [Related]
20. Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator. Sharma VK; Kawnayn G; Sarkar N Expert Rev Neurother; 2013 Aug; 13(8):895-902. PubMed ID: 23965163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]